Enveric Biosciences Announces Data that Broadens Scope of Clinical Indication Potential for Lead Candidate EB-003
Article content
EB-003 revealed to also act as an agonist of the serotonin receptor 5-HT1B, a validated target of drugs approved to treat major depressive disorder and a variety of neurological conditions including Parkinson's disease, migraines, and cluster headaches
Article content
Article content
CAMBRIDGE, Mass. — Enveric Biosciences (NASDAQ: ENVB) ('Enveric' or the 'Company'), a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders, today unveiled additional data indicating that its lead development candidate, EB-003, acts as an agonist of the serotonin receptor 5-HT1B, in addition to its other previously disclosed receptor engagement activities. The 5-HT1B receptor is a recognized therapeutic target for treating several central nervous system ('CNS') conditions, including major depressive disorder, Parkinson's disease, migraines, and cluster headaches.
Article content
The study results demonstrated agonism of 5-HT1B by EB-003 (EC 50 = 110 nM) and added to the existing receptor engagement data supporting that EB-003 acts as a partial agonist of the 5-HT2A receptor, which is key to the compound's potential ability to elicit neuroplastogenic effects without inducing adverse hallucinogenic outcomes.
Article content
'The 5-HT1B receptor, found predominantly in the frontal cortex, basal ganglia and hippocampus, is a validated therapeutic target of some well-known CNS drugs,' said Joseph Tucker, Ph.D., CEO of Enveric. 'Enveric previously announced positive pharmacology, in vitro safety and oral bioavailability data of EB-003, including achieving therapeutically relevant brain exposure in rodent models. The newly revealed ability to target 5-HT1B illustrates EB-003's differentiated and multifaceted mechanism of action and broadens its utility and the range of potential target indications to pursue in future development.'
Article content
EB-003 is currently in preclinical development, with IND-enabling activities planned to continue through 2025. Enveric Biosciences will continue to explore strategic therapeutic opportunities in the psychiatric and neurological markets to strengthen the target product profile of this novel CNS drug candidate.
Article content
About Enveric Biosciences
Article content
Enveric Biosciences (NASDAQ: ENVB) is a biotechnology company dedicated to the development of novel neuroplastogenic small-molecule therapeutics for the treatment of psychiatric and neurological disorders. Leveraging its unique discovery and development Psybrary™ platform, which houses proprietary information on the use and development of existing and novel molecules for specific mental health indications, Enveric seeks to develop a robust intellectual property portfolio of novel drug candidates. Enveric's lead molecule, EB-003, is a potential first-in-class neuroplastogen designed to promote neuroplasticity, without inducing hallucinations, in patients suffering from difficult-to-address mental health disorders. Enveric is focused on advancing EB-003 towards clinical trials for the treatment of neuropsychiatric disorders while out-licensing other novel, patented Psybrary™ platform drug candidates to third-party licensees advancing non-competitive market strategies for patient care. Enveric is headquartered in Naples, FL with offices in Cambridge, MA and Calgary, AB Canada. For more information, please visit www.enveric.com.
Article content
Forward-Looking Statements
Article content
This press release contains forward-looking statements and forward-looking information within the meaning of applicable securities laws. These statements relate to future events or future performance. All statements other than statements of historical fact may be forward-looking statements or information. Generally, forward-looking statements and information may be identified by the use of forward-looking terminology such as 'plans,' 'expects' or 'does not expect,' 'proposes,' 'budgets,' 'explores,' 'schedules,' 'seeks,' 'estimates,' 'forecasts,' 'intends,' 'anticipates' or 'does not anticipate,' or 'believes,' or variations of such words and phrases, or by the use of words or phrases which state that certain actions, events or results may, could, should, would, or might occur or be achieved. Forward-looking statements may include statements regarding beliefs, plans, expectations, or intentions regarding the future and are based on the beliefs of management as well as assumptions made by and information currently available to management. Actual results could differ materially from those contemplated by the forward-looking statements as a result of certain factors, including, but not limited to, the ability of Enveric to: finalize and submit its IND filing to the U.S. Food and Drug Administration; carry out successful clinical programs; achieve the value creation contemplated by technical developments; avoid delays in planned clinical trials; establish that potential products are efficacious or safe in preclinical or clinical trials; establish or maintain collaborations for the development of therapeutic candidates; obtain appropriate or necessary governmental approvals to market potential products; obtain future funding for product development and working capital on commercially reasonable terms; scale-up manufacture of product candidates; respond to changes in the size and nature of competitors; hire and retain key executives and scientists; secure and enforce legal rights related to Enveric's products, including patent protection; identify and pursue alternative routes to capture value from its research and development pipeline assets; continue as a going concern; and manage its future growth effectively.
Article content
A discussion of these and other factors, including risks and uncertainties with respect to Enveric, is set forth in Enveric's filings with the Securities and Exchange Commission, including Enveric's Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q. Enveric disclaims any intention or obligation to revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Article content
Article content
Article content
Article content
Contacts
Article content
Investor Relations
Tiberend Strategic Advisors, Inc.
David Irish
(231) 632-0002
dirish@tiberend.com Media Relations
Tiberend Strategic Advisors, Inc.
Casey McDonald
(646) 577-8520
cmcdonald@tiberend.com
Article content
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
an hour ago
- Globe and Mail
Argo Graphene Solutions Corp. Secures Purchase Agreement with Ceylon Graphene Technologies
VANCOUVER, British Columbia, July 31, 2025 (GLOBE NEWSWIRE) -- Argo Graphene Solutions Corp. (CSE: ARGO | OTCQB: ARLSF | Frankfurt: 94Y) ('Argo' or the 'Company'), a leader in innovative graphene-based technologies, is pleased to announce a purchase order with Ceylon Graphene Technologies (Pvt) Ltd. of Sri Lanka for one metric tonne of graphene oxide paste (approximately 20% pure graphene oxide). The purchase order includes 1,000 kg of graphene oxide paste, which is expected to yield approximately 50 tons of liquid dispersion for use as a direct additive in concrete. The paste will be packaged and shipped to Argo's mixing facility in Kenner, Louisiana, for final product preparation and distribution. This agreement marks a significant step toward establishing a long-term relationship with Ceylon Graphene to meet the growing global demand for high-purity graphene in the concrete, cement, and asphalt sectors. Argo's President and CEO, Scott Smale, visited Ceylon Graphene's facilities in Homagama, Sri Lanka in July of 2025. During the visit, Mr. Smale held productive discussions with Ceylon Graphene's CEO, Manju Gunawardana, and toured the company's laboratory and production facility, as well as the Sri Lanka Institute of Nanotechnology (SLINTEC), where advanced graphene characterization and testing are conducted. 'This purchase agreement is a pivotal milestone for Argo,' said Mr. Smale. 'Recent advancements in graphene production and new scientific testing highlight the transformative potential of graphene in the construction industry. We are excited to leverage this technology to deliver cutting-edge, sustainable solutions for the construction sector.' Recent scientific studies published in MDPI demonstrate that graphene-reinforced concrete offers significant improvements over conventional concrete, including a 44% increase in compressive strength, enhanced thermal conductivity, and a 200% reduction in maximum penetration depth. These findings underscore the potential of graphene-modified concrete to deliver superior mechanical strength, thermal regulation, and durability for advanced construction applications. Investor Relations Engagement Argo has engaged Cayo Ventures GmbH ('Cayo') (Grafenauweg 8, 6300 Zug, Switzerland, phone: 41765214100, e-mail: hello@ contact: Yves Toelderer), a marketing agency specializing in investor-focused digital advertising services. The agreement is for a term of three months, commencing on August 11, 2025, with either party having the right to terminate immediately. The Company has budgeted up to Fr$60,000 (Swiss Franc) per month for the marketing services of Cayo. The Company and Cayo maintain an arm's length relationship, and no securities will be issued as compensation for marketing services. About Argo Graphene Solutions Corp. Argo Graphene Solutions Corp. is a Canadian advanced materials company focused on developing sustainable, high-performance solutions for the construction and agricultural industries. Through its subsidiaries, including Argo Green Concrete Solutions Inc., Argo leverages cutting-edge technologies to create eco-friendly products that meet the demands of modern infrastructure. For further information, please contact: Scott Smale, CEO Argo Graphene Solutions Corp. Email: Phone: 306-596-2673 Website: The Canadian Securities Exchange has not reviewed this press release and does not accept responsibility for its adequacy or accuracy. Forward-Looking Statements Certain information in this press release constitutes 'forward-looking information' under Canadian securities legislation, including statements regarding the development of Argo's technology and the creation of eco-friendly products. Forward-looking statements are based on management's opinions and estimates as of the date of this release and are subject to known and unknown risks, uncertainties, and other factors that may cause actual results to differ materially. These factors include, but are not limited to, the receipt of necessary regulatory approvals. Argo undertakes no obligation to update forward-looking statements except as required by applicable securities laws. Readers should not place undue reliance on forward-looking information.
CTV News
2 hours ago
- CTV News
Trump says Canada backing statehood for Palestine makes it ‘very hard' to negotiate U.S. trade deal
Prime Minister Mark Carney and U.S. President Donald Trump meet at the White House in Washington, D.C., on May 6, 2025. (Adrian Wyld / The Canadian Press) U.S. President Donald Trump says Canada backing statehood for Palestine makes it 'very hard' for the United States to achieve a trade deal with its northern neighbour. 'Wow! Canada has just announced that it is backing statehood for Palestine,' Trump wrote in a post on Truth Social. 'That will make it very hard for us to make a Trade Deal with them. Oh' Canada!!!' Trump Truth Social Canada Palestine U.S. President Donald Trump says Canada recognizing statehood of Palestine makes it 'very hard' for two sides to reach trade deal. (Truth Social screenshot) The post comes hours before the president's Aug. 1 trade deadline, in which he's previously stated he would impose 35 per cent tariffs on Canada if the two sides could not come to an agreement. This is a late breaking update. Previous copy from The Canadian Press is below… Prime Minister Mark Carney said on Wednesday that Canada's negotiations with the United States might not conclude by Donald Trump's Aug. 1 deadline as the president added new trade measures that could further hinder some Canadian businesses. Carney said talks have been complex, comprehensive and constructive. He also said they are ongoing and cover 'a broad variety of topics.' 'There are many areas for co-operation between Canada and the United States, including defence spending, security spending, investments, which is one of the reasons why we're having these broader discussions,' Carney said at a news conference in Ottawa. Trump sent a letter to Carney threatening to impose 35 per cent tariffs if Canada doesn't make a trade deal by Friday. The White House has said those duties would not apply to goods compliant with the Canada-U.S.-Mexico Agreement on trade, better known as CUSMA. The Canadian economy is also being slammed by Trump's Section 232 tariffs on steel, aluminum and automobiles. Trump on Wednesday signed executive orders for 50 per cent tariffs on semi-finished copper products starting Friday. The president, however, didn't include imports of the refined metal in his order, leaving many in the Canadian copper industry feeling relieved. In a separate order, Trump suspended de minimis exemptions — which had allowed packages worth $800 or less to ship to the United States to avoid tariffs. As part of his reasoning for the change, Trump cited the flow of fentanyl into the United States. Canadian Federation of Independent Business President and CEO Dan Kelly said suspending the de minimis exemption 'is bad news for many Canadian small businesses.' The federation's data shows about one-third of small Canadian exporters used the exemption to ship to U.S. consumers duty free, Kelly said in a post on social media. Pascal Chan, the vice president of strategic policy and supply chains at the Canadian Chamber of Commerce, said it adds 'another layer of uncertainty for Canadian businesses exporting to the U.S.,' particularly small- and medium-sized businesses. 'Any increase in compliance costs and delivery delays will only serve to compound the pressure on the cross-border supply chains that have long fuelled our shared economic prosperity,' Chan said in a statement. The latest trade changes comes as countries around the world are set to face staggering tariffs when Trump's deadline to make deals passes. Trump announced a deal with South Korea Wednesday which will see the country slapped with a 15 per cent tariff. The president said South Korea 'will give to the United States $350 Billion Dollars for Investments owned and controlled by the United States, and selected by myself, as President. In apost on social media Trump said South Korea will also 'purchase $100 Billion Dollars of LNG, or other Energy products.' In a separate post the president also said he 'concluded a Deal with the Country of Pakistan, whereby Pakistan and the United States will work together on developing their massive Oil Reserves' but Trump didn't provide details of a tariff rate. Frameworks of deals have previously been announced for the European Union, Japan, Vietnam, Indonesia, the Philippines and the United Kingdom — with all nations facing some level of baseline tariff. Not all the details of the deals are clear but Trump has said countries can 'buy down' the tariff rate and most agreements have come with announcements of billion-dollar investments. Trump on Wednesday also escalated his threats against Brazil — which will be hit a 50 per cent duty — and India — which will face a 25 per cent tariff, plus an additional import tax because of India purchases Russian oil. Trump has been dismissive of conversations with Canada, saying it is not a priority for his administration. The president said Wednesday that America's northern neighbour is a high-tariff nation, misrepresenting Canadian duties for agriculture imports. 'They've been charging our farmers 200 per cent, 300 per cent, 400 per cent for years and nobody did anything about it,' Trump told reporters. Carney met virtually with his cabinet earlier Wednesday for a meeting focused largely on the situation in the Middle East. Carney said Canada is seeking the best deal for Canadians and that negotiations will continue until that is achieved. He said Dominic LeBlanc, the minister responsible for Canada-U.S. trade, will remain in Washington with senior officials 'in pursuit of that goal.' With files from Catherine Morrison This report by The Canadian Press was first published July 30, 2025 Kelly Geraldine Malone, The Canadian Press
Globe and Mail
2 hours ago
- Globe and Mail
Starbucks Reports Q3 2025 Financial Results
Starbucks ( (SBUX)) has released its Q3 earnings. Here is a breakdown of the information Starbucks presented to its investors. Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Starbucks Corporation, a leading global coffeehouse chain, operates in the specialty coffee industry, known for its high-quality arabica coffee and unique customer experience. In its Q3 Fiscal Year 2025 earnings report, Starbucks highlighted a 4% increase in consolidated net revenues to $9.5 billion, despite a 2% decline in global comparable store sales. The company's 'Back to Starbucks' strategy is showing progress, although earnings per share were impacted by one-time investments and tax items. Key financial metrics revealed a contraction in operating margins and a decrease in earnings per share, attributed to strategic investments and inflationary pressures. Starbucks opened 308 net new stores, with a significant presence in the U.S. and China, and reported a 9% increase in international segment revenues. Looking ahead, Starbucks remains focused on innovation and sustainable growth, as it continues to enhance customer service and operational efficiency.
